LFMD — LifeMD, Inc.

LifeMD, Inc. Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $50.2 million, exceeding guidance of $48-$49 million, but flat compared to $50.9 million in Q1 2025.
• Active Subscribers: Over 365,000, with a net addition of 42,000 in Q1, the largest quarterly increase in company history.
• Gross Margin: Expanded by approximately 420 basis points to 88%, attributed to improved shipping and fulfillment costs.
• Net Loss: GAAP net loss of $9.6 million ($0.20 per diluted share), compared to a loss of $2.4 million ($0.06 per diluted share) in the prior year.
• Adjusted EBITDA: Loss of approximately $4.5 million, in line with guidance, compared to a profit of $3.7 million in Q1 2025.
• Cash Position: Ended the quarter with $34.5 million in cash and no debt.

2. Strategic Updates and Business Highlights

• Weight Management: Significant growth with a 120% increase in sign-ups sequentially. The company is positioned to capitalize on the expanding GLP-1 therapy market.
• Women’s Health Program: Subscriber count increased over 7x from Q4, with retention rates above 80%. Plans to introduce seven new pharmacy products.
• RexMD and Men’s Health: Approximately 215,000 active patients, with growth in various categories including ED and sleep.
• AI Integration: LifeMD is embedding AI across its operations to enhance efficiency and personalize care.
• Pharmacy and Insurance Expansion: The pharmacy is processing 20,000 prescriptions per month, with plans to expand insurance coverage to approximately 230 million lives by the end of May.

3. Forward Guidance and Outlook

• Full-Year Guidance: Reaffirmed revenue guidance of $220 million to $230 million and adjusted EBITDA of $12 million to $17 million.
• Q2 Expectations: Projected revenue between $47 million and $50 million, with adjusted EBITDA ranging from negative $2 million to positive $1 million.
• Long-Term Goals: Anticipate annualized run-rate revenue exceeding $250 million and adjusted EBITDA exceeding $25 million by Q4 2026.

4. Bad News, Challenges, or Points of Concern

• Year-over-Year Revenue Decline: Revenue was flat compared to the prior year, raising concerns about growth sustainability.
• Increased Marketing Expenses: Selling and marketing expenses rose 34% year-over-year, impacting EBITDA.
• Transition to Branded Drugs: The shift from compounded GLP-1s to branded drugs may result in lower immediate revenues, although it is expected to improve long-term retention and unit economics.
• Competitive Pressures: The uptake of new oral therapies is being closely monitored, with some comparisons indicating slower adoption than expected.

5. Notable Q&A Insights

• Partnerships with Novo and Lilly: Management expressed optimism about evolving relationships with these pharmaceutical companies, which are expected to enhance patient access to therapies.
• Insurance-Supported Programs: Significant improvements in retention rates and a reduction in customer acquisition costs for patients using insurance were highlighted.
• Market Dynamics: The company is seeing strong demand for oral therapies, and the success of self-pay programs has exceeded expectations.
• Future Initiatives: Plans to expand pharmacy offerings and technical improvements are expected to drive revenue and EBITDA growth in the second half of 2026.

In summary, LifeMD, Inc. had a strong start to 2026 with record subscriber growth and strategic advancements, although challenges remain regarding revenue sustainability and the transition to branded therapies. The company is optimistic about its future trajectory, backed by strong partnerships and expanding market opportunities.